Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bruns, C. J.
Right arrow Articles by Fidler, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruns, C. J.
Right arrow Articles by Fidler, I. J.
[Cancer Research 60, 2926-2935, June 1, 2000]
© 2000 American Association for Cancer Research


Experimental Therapeutics

Blockade of the Epidermal Growth Factor Receptor Signaling by a Novel Tyrosine Kinase Inhibitor Leads to Apoptosis of Endothelial Cells and Therapy of Human Pancreatic Carcinoma1

Christiane J. Bruns, Carmen C. Solorzano, Matthew T. Harbison, Shutaro Ozawa, Rachel Tsan, Dominic Fan, James Abbruzzese, Peter Traxler, Elisabeth Buchdunger, Robert Radinsky and Isaiah J. Fidler2

Departments of Cancer Biology [C. J. B., C. C. S., M. T. H., S. O., R. T., D. F., R. R., I. J. F.] and Gastrointestinal Oncology and Digestive Diseases [J. A.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Novartis Pharma, CH-4002 Basel, Switzerland [P. T., E. B.]

We determined whether down-regulation of the epidermal growth factor-receptor (EGF-R) signaling pathway by oral administration of a novel EGF-R tyrosine kinase inhibitor (PKI166) alone or in combination with gemcitabine (administered i.p.) can inhibit growth and metastasis of human pancreatic carcinoma cells implanted into the pancreas of nude mice. Therapy beginning 7 days after orthotopic injection of L3.6pl human pancreatic cancer cells reduced the volume of pancreatic tumors by 59% in mice treated with gemcitabine only, by 45% in those treated with PKI166 only, and by 85% in those given both drugs. The combination therapy also significantly inhibited lymph node and liver metastasis, which led to a significant increase in overall survival. EGF-R activation was significantly blocked by therapy with PKI166 and was associated with significant reduction in tumor cell production of VEGF and IL-8, which in turn correlated with a significant decrease in microvessel density and an increase in apoptotic endothelial cells. Collectively, our results demonstrate that oral administration of an EGF-R tyrosine kinase inhibitor decreased growth and metastasis of human pancreatic cancer growing orthotopically in nude mice and increased survival. The therapeutic effects were mediated in part by inhibition of tumor-induced angiogenesis attributable to a decrease in production of proangiogenic molecules by tumor cells and increased apoptosis of tumor-associated endothelial cells.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
A. Kleespies, I. Ischenko, M. E. Eichhorn, H. Seeliger, C. Amendt, O. Mantell, K.-W. Jauch, and C. J. Bruns
Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine
Clin. Cancer Res., September 1, 2008; 14(17): 5426 - 5436.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, et al.
Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Clin. Cancer Res., August 15, 2008; 14(16): 5069 - 5080.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Croyle, N. Akeno, J. A. Knauf, D. Fabbro, X. Chen, J. E. Baumgartner, H. A. Lane, and J. A. Fagin
RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR
Cancer Res., June 1, 2008; 68(11): 4183 - 4191.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. Normanno and A. De Luca
Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?
J. Clin. Oncol., December 20, 2007; 25(36): 5836 - 5837.
[Full Text] [PDF]


Home page
Cancer Res.Home page
T. Shimamura, R. E. Royal, M. Kioi, A. Nakajima, S. R. Husain, and R. K. Puri
Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Cancer Res., October 15, 2007; 67(20): 9903 - 9912.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H.-W. Lo, S.-C. Hsu, W. Xia, X. Cao, J.-Y. Shih, Y. Wei, J. L. Abbruzzese, G. N. Hortobagyi, and M.-C. Hung
Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression
Cancer Res., October 1, 2007; 67(19): 9066 - 9076.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Lange, M. Kammerer, M. E. Hegi, S. Grotegut, A. Dittmann, W. Huang, E. Fluri, G. W. Yip, M. Gotte, C. Ruiz, et al.
Endothelin Receptor Type B Counteracts Tenascin-C-Induced Endothelin Receptor Type A-Dependent Focal Adhesion and Actin Stress Fiber Disorganization
Cancer Res., July 1, 2007; 67(13): 6163 - 6173.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, H. J. Au, P. Murawa, D. Walde, R. A. Wolff, et al.
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., May 20, 2007; 25(15): 1960 - 1966.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Zhang, J. A.F. Hannay, J. Liu, P. Das, M. Zhan, T. Nguyen, D. J. Hicklin, D. Yu, R. E. Pollock, and D. Lev
Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance.
Cancer Res., September 1, 2006; 66(17): 8770 - 8778.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. V. Heymach, M. Nilsson, G. Blumenschein, V. Papadimitrakopoulou, and R. Herbst
Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4441s - 4445s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. A. Adjei
Novel combinations based on epidermal growth factor receptor inhibition.
Clin. Cancer Res., July 15, 2006; 12(14): 4446s - 4450s.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. N. Younes, Y. D. Yazici, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers
Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer.
Clin. Cancer Res., June 1, 2006; 12(11): 3425 - 3434.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho
Genetics and biology of pancreatic ductal adenocarcinoma.
Genes & Dev., May 15, 2006; 20(10): 1218 - 1249.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. R. Camp, A. Yang, W. Liu, F. Fan, R. Somcio, D. J. Hicklin, and L. M. Ellis
Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer
Clin. Cancer Res., April 15, 2006; 12(8): 2628 - 2633.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. L. Gable, B. A. Maddux, C. Penaranda, M. Zavodovskaya, M. J. Campbell, M. Lobo, L. Robinson, S. Schow, J. A. Kerner, I. D. Goldfine, et al.
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
Mol. Cancer Ther., April 1, 2006; 5(4): 1079 - 1086.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
S. S. Yoon, S. H. Kim, M. Gonen, N. M. Heffernan, K. Y. Detwiller, W. R. Jarnagin, M. D'Angelica, L. H. Blumgart, K. K. Tanabe, and R. P. DeMatteo
Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases
Ann. Surg. Oncol., March 1, 2006; 13(3): 353 - 362.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. G. Trevino, J. M. Summy, D. P. Lesslie, N. U. Parikh, D. S. Hong, F. Y. Lee, N. J. Donato, J. L. Abbruzzese, C. H. Baker, and G. E. Gallick
Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model
Am. J. Pathol., March 1, 2006; 168(3): 962 - 972.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al.
Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice
Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Bozec, P. Formento, J. Ciccolini, R. Fanciullino, L. Padovani, X. Murraciole, J.-L. Fischel, and G. Milano
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation
Mol. Cancer Ther., December 1, 2005; 4(12): 1962 - 1971.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. G. Trevino, J. M. Summy, M. J. Gray, M. B. Nilsson, D. P. Lesslie, C. H. Baker, and G. E. Gallick
Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis
Cancer Res., August 15, 2005; 65(16): 7214 - 7222.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
S. N. Holden, S. G. Eckhardt, R. Basser, R. de Boer, D. Rischin, M. Green, M. A. Rosenthal, C. Wheeler, A. Barge, and H. I. Hurwitz
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
Ann. Onc., August 1, 2005; 16(8): 1391 - 1397.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood
The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade
Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al.
Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation
Cancer Res., June 1, 2005; 65(11): 4716 - 4727.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhang, S. Banerjee, Z.-w. Wang, D. J. Marciniak, A. P.N. Majumdar, and F. H. Sarkar
Epidermal Growth Factor Receptor-Related Protein Inhibits Cell Growth and Induces Apoptosis of BxPC3 Pancreatic Cancer Cells
Cancer Res., May 1, 2005; 65(9): 3877 - 3882.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Kim, B. A. Schiff, O. G. Yigitbasi, D. Doan, S. A. Jasser, B. N. Bekele, M. Mandal, and J. N. Myers
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
Mol. Cancer Ther., April 1, 2005; 4(4): 632 - 640.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. P. Schneider and K. D. Miller
Angiogenesis of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1782 - 1790.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. W. Park, M. N. Younes, S. A. Jasser, O. G. Yigitbasi, G. Zhou, C. D. Bucana, B. N. Bekele, and J. N. Myers
AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice
Clin. Cancer Res., March 1, 2005; 11(5): 1963 - 1973.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor
Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al.
Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668
Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. C. Lev, S. J. Kim, A. Onn, V. Stone, D.-H. Nam, S. Yazici, I. J. Fidler, and J. E. Price
Inhibition of Platelet-Derived Growth Factor Receptor Signaling Restricts the Growth of Human Breast Cancer in the Bone of Nude Mice
Clin. Cancer Res., January 1, 2005; 11(1): 306 - 314.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Onn, T. Isobe, W. Wu, S. Itasaka, T. Shintani, K. Shibuya, Y. Kenji, M. S. O'Reilly, I. J. Fidler, and R. S. Herbst
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer
Clin. Cancer Res., December 15, 2004; 10(24): 8613 - 8619.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. H. Um, J. K. Kwon, C.-D. Kang, M. J. Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung, and S. H. Kim
Relationship between Antiapoptotic Molecules and Metastatic Potency and the Involvement of DNA-Dependent Protein Kinase in the Chemosensitization of Metastatic Human Cancer Cells by Epidermal Growth Factor Receptor Blockade
J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1062 - 1070.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. V. Yezhelyev, G. Koehl, M. Guba, T. Brabletz, K.-W. Jauch, A. Ryan, A. Barge, T. Green, M. Fennell, and C. J. Bruns
Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice
Clin. Cancer Res., December 1, 2004; 10(23): 8028 - 8036.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. G. Yigitbasi, M. N. Younes, D. Doan, S. A. Jasser, B. A. Schiff, C. D. Bucana, B. N. Bekele, I. J. Fidler, and J. N. Myers
Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade
Cancer Res., November 1, 2004; 64(21): 7977 - 7984.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Takada, H. M. Weiss, O. Kretz, G. Gross, and Y. Sugiyama
HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154
Drug Metab. Dispos., November 1, 2004; 32(11): 1272 - 1278.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. F. McCarty, J. Wey, O. Stoeltzing, W. Liu, F. Fan, C. Bucana, P. F. Mansfield, A. J. Ryan, and L. M. Ellis
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer
Mol. Cancer Ther., September 1, 2004; 3(9): 1041 - 1048.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Emanuel, R. H. Gruninger, A. Fuentes-Pesquera, P. J. Connolly, J. A. Seamon, S. Hazel, R. Tominovich, B. Hollister, C. Napier, M. R. D'Andrea, et al.
A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models
Mol. Pharmacol., September 1, 2004; 66(3): 635 - 647.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Z. Chen, X. Zhang, M. Li, Z. Wang, H. S. Wieand, J. R. Grandis, and D. M. Shin
Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., September 1, 2004; 10(17): 5930 - 5939.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. H. Lorch, J. Klessner, J. K. Park, S. Getsios, Y. L. Wu, M. S. Stack, and K. J. Green
Epidermal Growth Factor Receptor Inhibition Promotes Desmosome Assembly and Strengthens Intercellular Adhesion in Squamous Cell Carcinoma Cells
J. Biol. Chem., August 27, 2004; 279(35): 37191 - 37200.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Zingg, O. Riesterer, D. Fabbro, C. Glanzmann, S. Bodis, and M. Pruschy
Differential Activation of the Phosphatidylinositol 3'-Kinase/Akt Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells
Cancer Res., August 1, 2004; 64(15): 5398 - 5406.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Traxler, P. R. Allegrini, R. Brandt, J. Brueggen, R. Cozens, D. Fabbro, K. Grosios, H. A. Lane, P. McSheehy, J. Mestan, et al.
AEE788: A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity
Cancer Res., July 15, 2004; 64(14): 4931 - 4941.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. J. Kim, H. Uehara, S. Yazici, R. R. Langley, J. He, R. Tsan, D. Fan, J. J. Killion, and I. J. Fidler
Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice
Cancer Res., June 15, 2004; 64(12): 4201 - 4208.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. C. Lev, A. Onn, V. O. Melinkova, C. Miller, V. Stone, M. Ruiz, E. C. McGary, H. N. Ananthaswamy, J. E. Price, and M. Bar-Eli
Exposure of Melanoma Cells to Dacarbazine Results in Enhanced Tumor Growth and Metastasis In Vivo
J. Clin. Oncol., June 1, 2004; 22(11): 2092 - 2100.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Y. Wu, L. Chen, L. Cao, W. Sheng, and B. B. Yang
Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and {beta}1-integrin
J. Cell Sci., May 1, 2004; 117(11): 2227 - 2237.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Wu, C. Parungo, G. Wu, P. M. Kang, R. J. Laham, F. W. Sellke, M. Simons, and J. Li
PR39 Inhibits Apoptosis in Hypoxic Endothelial Cells: Role of Inhibitor Apoptosis Protein-2
Circulation, April 6, 2004; 109(13): 1660 - 1667.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Yokoi and I. J. Fidler
Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine
Clin. Cancer Res., April 1, 2004; 10(7): 2299 - 2306.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Olszewska-Pazdrak, K. L. Ives, J. Park, C. M. Townsend Jr., and M. R. Hellmich
Epidermal Growth Factor Potentiates Cholecystokinin/Gastrin Receptor-mediated Ca2+ Release by Activation of Mitogen-activated Protein Kinases
J. Biol. Chem., January 16, 2004; 279(3): 1853 - 1860.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al.
Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy
Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, and D. J. McConkey
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts
Mol. Cancer Ther., January 1, 2004; 3(1): 59 - 70.
[Abstract] [Full Text]


Home page
The OncologistHome page
M. L. Janmaat and G. Giaccone
Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, December 1, 2003; 8(6): 576 - 586.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
Ann. Onc., September 1, 2003; 14(9): 1346 - 1363.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Williams, C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D. J. McConkey
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts
Mol. Cancer Ther., September 1, 2003; 2(9): 835 - 843.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
O. Stoeltzing, W. Liu, N. Reinmuth, F. Fan, A. A. Parikh, C. D. Bucana, D. B. Evans, G. L. Semenza, and L. M. Ellis
Regulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer
Am. J. Pathol., September 1, 2003; 163(3): 1001 - 1011.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. She, F. Lee, J. Chen, A. Haimovitz-Friedman, V. A. Miller, V. R. Rusch, M. G. Kris, and F. M. Sirotnak
The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Selectively Potentiates Radiation Response of Human Tumors in Nude Mice, with a Marked Improvement in Therapeutic Index
Clin. Cancer Res., September 1, 2003; 9(10): 3773 - 3778.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. C. Holsinger, D. D. Doan, S. A. Jasser, E. A. Swan, J. S. Greenberg, B. A. Schiff, B. N. Bekele, M. N. Younes, C. D. Bucana, I. J. Fidler, et al.
Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer
Clin. Cancer Res., August 1, 2003; 9(8): 3183 - 3189.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J. M. Cherrington, E. Scanziani, M. I. Nicoletti, et al.
The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically
Clin. Cancer Res., August 1, 2003; 9(9): 3476 - 3485.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Mendelsohn and J. Baselga
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799.
[Abstract] [Full Text] [PDF]